Dr Véronique Walsh joins BMS UK

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience

Bristol-Myers Squibb (BMS) UK has appointed Dr Véronique Walsh to the role of business unit director, neuroscience and immunoscience. She will report to vice president and general manager of BMS UK, Amadou Diarra.

Dr Véronique Walsh

Dr Walsh will lead the sales and marketing teams for BMS' neuroscience and immunoscience portfolio which includes Orencia (abatacept), Abilify (aripiprazole) and Perfalgan (paracetamol IV), as well as investigational products.

Most recently serving as deputy managing director at Sanofi Pasteur MSD UK, and in charge of market access, public affairs, communications, and strategic planning, Dr Walsh has 20 years experience in the vaccines industry. Key achievements during her 14 years at Sanofi Pasteur MSD include the launch of several new vaccines and the development and implementation of market access strategies within the company. 

Before joining the pharmaceutical industry in 1990, Dr Walsh held different hospital and primary care positions in France. She has an MBA from the Business School in Lyon, France, and has completed the Runge Balliol leadership in management course at Oxford. In 2010, she also gained a post graduate certificate in health economics for health professionals from the University of York. 

Latest intelligence

New Playbook Alert: Virtual Patient Engagement

...

Millennials: the wellness generation

Looking at the results from a global healthcare research study focusing on the patients of the future...

The problem with clinical trials (and how virtual insight-gathering can help)

While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....